What's Happening?
Novartis has announced promising results from its Phase 1/2 FORTITUDE study involving the investigational RNA medicine delpacibart braxlosiran (del-brax) for treating facioscapulohumeral muscular dystrophy (FSHD). The study enrolled 90 patients who received
either del-brax or a placebo. The primary outcome focused on the treatment's effect on KHDC1L, a plasma disease biomarker for FSHD. Novartis reported that the biomarker cohort met its primary and key secondary endpoints, with reduced KHDC1L levels in patients treated with del-brax, indicating strong target engagement. Additionally, del-brax led to a decrease in creatine kinase concentrations, suggesting a reduction in muscle damage. These findings replicate earlier results showing improved muscle function in patients treated with del-brax.
Why It's Important?
The results from the FORTITUDE study are significant as they demonstrate the potential of del-brax to effectively target and treat FSHD, a rare and progressive neuromuscular disease affecting thousands in the U.S. and Europe. The success of del-brax could lead to a new treatment option for patients suffering from this debilitating condition, which currently has limited therapeutic options. The study's findings also highlight the potential of RNA-based therapies in addressing genetic disorders, offering hope for advancements in treating other rare neuromuscular diseases. Novartis' investment in Avidity Biosciences and its RNA-based therapies underscores the growing interest and potential in this area of medical research.
What's Next?
Novartis plans to evaluate the totality of the biomarker and clinical data from the FORTITUDE study and engage in discussions with global regulatory agencies. The company has also initiated the Phase 3 FORTITUDE-3 trial, aiming to enroll around 200 patients to further assess the effects of del-brax on muscle performance. The outcome of these trials will be crucial in determining the future of del-brax as a treatment for FSHD and could lead to regulatory approval and commercialization. The success of these trials could also pave the way for further research and development of RNA-based therapies for other genetic disorders.
